Table 2 –
Number of patients from each centre in GAP3 at 5 yr of follow-up
| Centre | Still on AS | Still on AS, follow-up <5 yr | Lost to follow-up | Progression | Converted to active treatment | Watchful waiting | Death from other causes | Total |
|---|---|---|---|---|---|---|---|---|
| EU-Atlanta | 5 | 41 | 0 | 2 | 0 | 0 | 0 | 48 |
| KB-Baden | 44 | 52 | 0 | 22 | 24 | 2 | 1 | 145 |
| UOF-Calgary | 82 | 346 | 0 | 80 | 30 | 0 | 0 | 538 |
| CUHT-Cambridge | 21 | 162 | 14 | 18 | 7 | 1 | 1 | 224 |
| EMC-Rotterdam | 49 | 18 | 3 | 33 | 4 | 5 | 0 | 112 |
| other PRIAS centres | 149 | 1368 | 26 | 392 | 136 | 51 | 13 | 2135 |
| SU-Gothenburg | 293 | 147 | 1 | 111 | 142 | 0 | 43 | 737 |
| HUCH-Helsinki | 58 | 97 | 1 | 97 | 9 | 17 | 3 | 282 |
| JHU-Baltimore | 461 | 315 | 91 | 400 | 141 | 0 | 9 | 1417 |
| KU-Kagawa | 29 | 2 | 1 | 45 | 19 | 3 | 5 | 104 |
| CHU-Lille | 4 | 94 | 10 | 36 | 10 | 0 | 1 | 155 |
| GSTT-London | 58 | 43 | 0 | 83 | 8 | 0 | 2 | 194 |
| UCL-London | 30 | 230 | 0 | 0 | 10 | 2 | 0 | 272 |
| SUS-Malmö | 10 | 90 | 1 | 19 | 4 | 1 | 1 | 126 |
| MEASCAP-Melbourne | 53 | 114 | 0 | 63 | 3 | 3 | 0 | 236 |
| INT-Milan | 102 | 287 | 0 | 245 | 51 | 23 | 2 | 710 |
| MSKCC-New York | 443 | 344 | 0 | 56 | 190 | 0 | 16 | 1049 |
| YUHS-Seoul | 0 | 33 | 0 | 2 | 1 | 0 | 0 | 36 |
| SGH-Singapore | 21 | 93 | 0 | 20 | 46 | 0 | 1 | 181 |
| UCSF-San Francisco | 405 | 487 | 0 | 262 | 94 | 0 | 11 | 1259 |
| IVO-Valencia | 22 | 149 | 0 | 61 | 21 | 10 | 5 | 268 |
| UBC-Vancouver | 0 | 49 | 1 | 14 | 2 | 0 | 2 | 68 |
| Total | 2339 | 4561 | 149 | 2061 | 952 | 118 | 116 | 10 296 |
GAP3 = Movember’s Global Action Plan Prostate Cancer Active Surveillance initiative; KCL = King's College London; Erasmus MC = Erasmus Medical Center; MSKCC = Memorial Sloan Kettering Cancer Center; PRIAS = Prostate Cancer Research International Active Surveillance; UCL = University College London; UCSF = University of California, San Francisco. See appendix A for institute abbreviations.